OBJECTIVE: To evaluate the duration of protection of pentavaent rotavirus vaccine (RV5)
against rotavirus hospitalizations in Nicaragua, a developing country in Central America …

Context Pentavalent rotavirus vaccine (RV5), a live, oral attenuated vaccine, prevented 98%
of severe rotavirus diarrhea in a trial conducted mainly in Finland and the United States …

Background: In 2006, Merck & Co., Inc., partnered with the Nicaraguan Ministry of Health to
demonstrate the public health impact of routine universal vaccination by delivering more …

Background. Concerns remain about lower effectiveness and waning immunity of rotavirus
vaccines in resource-poor populations. We assessed vaccine effectiveness against rotavirus …

Objective To assess the effectiveness of the monovalent rotavirus vaccine (RV1) to prevent
rotavirus diarrhea admissions to emergency departments (ED) in Colombia. Methods A …

Objective Using case-control methodology, we measured the vaccine effectiveness (VE) of
the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine …

OBJECTIVE: To determine the vaccine effectiveness (VE) of complete and partial
vaccination with the pentavalent rotavirus vaccine (RV5) in the prevention of rotavirus acute …

Abstract Background. The Republic of Armenia was 1 of the 2 earliest countries in the Newly
Independent States to introduce rotavirus vaccine into its national immunization program to …

Abstract Background RotaTeq™(RV5; Merck & Co. Inc., USA) and Rotarix™(RV1,
GlaxoSmithKline, Belgium) vaccines, developed to prevent rotavirus diarrhea in children …

Background: Although the pentavalent rotavirus vaccine was highly efficacious against
rotavirus diarrhea in clinical trials, the effectiveness of vaccine under field conditions in the …